Lantern Pharma

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company committed to innovating, revitalizing, and advancing precision oncology therapeutics. By utilizing a proprietary AI platform to discover biomarker signatures and leveraging advanced technologies in machine learning, genomics, and artificial intelligence, Lantern helps identify patients more likely to respond to our cancer treatment methods. The company’s focus is on improving patient outcomes by employing its technology to discover, rescue, and develop abandoned or failed drugs. Its current portfolio includes three drug candidates: two in clinical stages and two in preclinical stages, targeting cancers with distinct and underserved clinical needs in well-defined or undefined patient populations. Lantern believes that the use of machine learning, genomics, and computational approaches can accelerate the revival, refocusing, and redevelopment of small-molecule therapies. By matching drugs to patients based on their genomic profiles to identify those most likely to benefit, this approach represents the potential for delivering optimal outcomes. The team seeks experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory strategies to help bring cancer treatments to patients as quickly and efficiently as possible.